Ocular Therapeutix (NASDAQ: OCUL) announced positive topline data from the first of two Phase 3 clinical trials evaluating the safety ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Ocular Therapeutix (OCUL) Target Raised to $49 at Oppenheimer; Positive Data Validates PlatformMarch 11, 2015 7:38 AM Ocular Therapeutix (OCUL) Price Target Raised to $50 at RBCMarch 10, 2015 3:59 PM Ocular Therapeutix (OCUL) Tops Q4 EPS by 1cMarch 10, 2015 6:46 AM Ocular Therapeutix™ Reports Positive Topline Clinical Data for the First of Two Phase 3 Clinical Trials Evaluating OTX-DP for the Treatment of Post-Surgical Ocular Inflammation and PainMarch 10, 2015 6:30 AM Form 4 OCULAR THERAPEUTIX, INC For: Jul 30 Filed by: Ankerud EricMarch 6, 2015 6:58 PM